Back to User profile » Mr Thomas Bengtsson
Papers published by Mr Thomas Bengtsson:
Relative Bioavailability of Inhaled Fluticasone Propionate and Salmeterol – is Population Pharmacokinetic Modelling a Relevant Alternative to a Non-Compartmental Approach?
Rosenborg J, Bäckman P, Bengtsson T, Haughie S
Drug Design, Development and Therapy 2025, 19:9653-9670
Published Date: 27 October 2025
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1611-1622
Published Date: 28 July 2023
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
Ferguson GT, Kerwin EM, Rheault T, Bengtsson T, Rickard K
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1137-1148
Published Date: 22 April 2021
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
Watz H, Rickard K, Rheault T, Bengtsson T, Singh D
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2199-2206
Published Date: 16 September 2020
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)
Bjermer L, Kuna P, Jorup C, Bengtsson T, Rosenborg J
Drug Design, Development and Therapy 2015, 9:753-762
Published Date: 5 February 2015